![ECOG-ACRIN logo[19516]275×75](https://blog.ecog-acrin.org/wp-content/uploads/2021/03/ECOG-ACRIN-logo19516275x75.png)
February 27, 2026
Liquid biopsies are now permitted for eligibility determination, while trial participants may use progression biopsies to explore treatment options
November 25, 2024
Fall Group Meeting highlights; impactful results in head and neck cancer; a ComboMATCH update
September 17, 2024
A conversation with study chair James M. Ford, MD
February 9, 2024
This phase 2 trial is evaluating the combination of two different types of targeted drugs—sotorasib and panitumumab—that appear to be synergistic
October 19, 2023
Summaries and links to timely information about research results in medical journals, recognition of research leaders, and more
June 30, 2023
Reflections on the spring conference season, including highlights from the recent Group Meeting; updates on the ComboMATCH precision medicine initiative
June 30, 2023
This phase 2 trial is evaluating the activity of nilotinib-paclitaxel in patients with solid tumors and exploring predictive biomarkers of response and resistance
April 19, 2023
The ComboMATCH registration trial opens; NCI creates Clinical Trials Innovation unit, unveils revised National Cancer Plan
April 19, 2023
ComboMATCH researchers are discovering new drug combinations that show promise for patients with advanced cancers, based on strong pre-clinical in vivo evidence of therapeutic effectiveness
April 15, 2022
In an enormous undertaking, ECOG-ACRIN and the NCI have built the knowledge base and infrastructure for future precision medicine trials. The new Genomics Subcommittee is offering expertise moving forward.
July 29, 2020
